3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
15
Leukemia, Lymphocytic, Chronic, B-Cell
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Lymphoma, Follicular
12
Recurrence
10
Lymphoma, Mantle-Cell
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma
9
Lymphoma, B-Cell, Marginal Zone
8
Leukemia
7
Lymphoma, B-Cell
6
Neoplasms
4
Leukemia, Myeloid, Acute
4
Burkitt Lymphoma
4
Melanoma
3
Lymphoma, Large-Cell, Anaplastic
3
Hematologic Neoplasms
3
Carcinoma, Renal Cell
3
Waldenstrom Macroglobulinemia
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neuroblastoma
2
Mastocytosis, Systemic
2
Lymphoproliferative Disorders
2
Lung Neoplasms
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Mast-Cell
2
Leukemia, Biphenotypic, Acute
2
Hodgkin Disease
2
Hematologic Diseases
2
Interventions
loncastuximab tesirine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Diffuse Large B-Cell Lymphoma Refractory
×
Lymphoid
×
Clear all
NCT03589469
2023-08-29
LOTIS-2
ADC Therapeutics S.A.
Phase 2
Completed
145 enrolled
24 charts
1 FDA